Board of
Directors

An active and powerful board of experienced professionals drives us to our greatest level of success.

Maria Sainz

President & CEO

Maria Sainz was appointed President and CEO of AEGEA Medical in May 2018. She has over 25 years’ experience in commercial and leadership positions in … Read more

Maria Sainz - President & CEO

Maria Sainz was appointed President and CEO of AEGEA Medical in May 2018. She has over 25 years’ experience in commercial and leadership positions in the medtech industry. Maria has served as the President and CEO of Cardiokinetix, a medical device company pioneering a catheter-based treatment for heart failure. Prior to that, Maria was the President and CEO of Concentric Medical, Inc., a developer of minimally invasive products for the treatment of acute ischemic stroke which was acquired in 2011 by Stryker Corporation. Maria began her medtech career at Guidant Corporation where she held positions of increasing responsibility in Europe and the US. At the time of the acquisition of Guidant by Boston Scientific, Maria served as President of the Cardiac Surgery division of Guidant Corporation. Maria has been intimately involved in several major medtech product launches such as coronary stents or cardiac resynchronization therapy devices. Maria also serves as a director of several public and private medical company boards. She received an M.A in Languages from the University Complutense in Madrid, Spain and a Masters in International Management from the American Graduate School of International Management.

David Adair MD

Director – Solas BioVentures

Dr. Adair is a managing partner and co-founder of Solas BioVentures. He currently focuses on investments in medical device and therapeutic companies. Board certified in … Read more

David Adair MD - Director – Solas BioVentures

Dr. Adair is a managing partner and co-founder of Solas BioVentures. He currently focuses on investments in medical device and therapeutic companies. Board certified in Maternal-Fetal Medicine, Obstetrics and Gynecology, and Hypertension, and having special experience in Critical Care, Dr. Adair is a long-time physician, educator, administrator, innovator, and biotech/med-tech investor with nearly 20 years of experience in angel and venture investing. Dr. Adair currently serves as Professor, Vice Chairman of the Department of Obstetrics and Gynecology at the University of Tennessee College of Medicine. He is an active candidate for his MBA in Healthcare at the University of Tennessee Chattanooga. Dr. Adair received a BS in Biology from Morehead State University (1986), and an MD from the Joan C. Edwards College of Medicine at Marshall University in 1990. He completed residency at the University of Florida Health Science Center and Fellowship training at Wake Forest University.

Dave serves on the board of directors for NxPhase Medical, Arrivo Bio, Advanced Catheter Therapies, PreTel Health, Velo Bio and Anogen Therapeutics. Dr. Adair and his colleagues have invested in many cutting edge and disruptive medical device and biotech companies, including Veran Medical Technologies (where he served previously as a board director), Addrenex (acquired by Sciele/Shionogi), Neuronex (acquired by Acorda), Aerial Bio (acquired by Jazz Pharmaceuticals), and NxThera (acquired by Boston Scientific). Dr. Adair also founded Glenveigh Pharmaceuticals, which had products out-licensed to Protherics and acquired by Clinical Innovations.

Josh Baltzell

Director – Sightline Partners

Josh is a Venture Partner at Sightline Partners, and also serves as a Venture Partner at Split Rock Partners.  He has been with Sightline since … Read more

Josh Baltzell - Director – Sightline Partners

Josh is a Venture Partner at Sightline Partners, and also serves as a Venture Partner at Split Rock Partners.  He has been with Sightline since 2014 and with Split Rock since 2004.  Mr. Baltzell has over 25 years of experience in the healthcare industry.

Prior to his tenure in the venture capital industry, Josh held roles as an investment banker at Piper Jaffray Companies from 2000 to 2002, where he focused primarily on mergers and acquisitions in the medical device sector as well as various marketing and business and development positions with SCIMED and Boston Scientific.  Josh currently serves on the boards of Colorescience, Magnolia Medical, Histogenics Corporation (NASDAQ: HSGX) and ViewPoint Medical.

Josh’s previous investments and board affiliations have resulted in several M&A transactions including Entellus Medical (Stryker), Ardian (Medtronic), Dfine (Merit Medical), RF Surgical (Medtronic), Skinmedica (Allergan) and Tarsus (Integra Lifesciences).

Josh holds a B.A. in Economics from St. Olaf College and an MBA from the University of Minnesota’s Carlson School of Management.

Paul Goeld

Director – Sightline Partners

Paul Goeld is the founder and Executive Chairman of AEGEA Medical. He is also the Managing Director of Keystone Advisors, a firm that provides advisory … Read more

Paul Goeld - Director – Sightline Partners

Paul Goeld is the founder and Executive Chairman of AEGEA Medical. He is also the Managing Director of Keystone Advisors, a firm that provides advisory services for early-stage medical device companies and private equity firms.

Paul has been a founder, CEO or Director of several medical device companies including CoAlign Innovations (acquired by Stryker), Adiana (acquired by Hologic), Pilot Cardiovascular (acquired by C. R. Bard), ESTECH (acquired by Atricure), General Surgical Innovations (public and acquired by Tyco), Camino Laboratories (now Integra Life Sciences) as well as private, venture-backed companies Relievant Medsystems, Gynesonics, Intuity Medical, Baronova, and Bioventrix.

Doug Kelly MD

Director - Alloy Ventures

Doug Kelly has worked with the partners of Alloy Ventures since 1993 and was a founding member of the firm. He currently focuses on investments … Read more

Doug Kelly MD - Director - Alloy Ventures

Doug Kelly has worked with the partners of Alloy Ventures since 1993 and was a founding member of the firm. He currently focuses on investments in medical device companies.

Trained as a physician, Doug is a long-time venture investor with 20 years of experience in bridging the needs of the business and medical communities with novel applications of technology to create world-class companies. Prior to joining Alloy Ventures, he worked for two European venture capital firms, in business development at Ligand Pharmaceuticals, and as an independent consultant. Additionally, Doug teaches “Business 16 Financing The Startup” at Stanford University. Doug received a BA in Biochemistry and Cell Biology from the University of California at San Diego (1983), an MD from the Albert Einstein College of Medicine in 1988, and an MBA from Stanford University (1990).

Doug also serves on the board of directors for Restoration Robotics. Doug has invested in many leading medical device and biotech companies, and previously served on the boards of Sapient Health Network (acquired by WebMD/Healtheon in 1999), Camitro (acquired by Arqule in 2001), Fusion Medical (acquired by Baxter in 2002), Integrated Biosystems (acquired by Stedim SA in 2004), Adiana (acquired by Cytyc/Hologic in 2007), Pharsight (acquired by Tripos in 2008), Barrx Medical (acquired by Covidien in January 2012), Cameron Health (acquired by Boston Scientific in June 2012), Crux Biomedical (acquired by Volcano Corp. in December 2012), and CoAlign Innovations (acquired by Stryker in March, 2014).

David Douglass

Director - Delphi Ventures

Since 1979, David has been actively involved in managing and investing in over 50 high growth venture capital backed companies, primarily in the medical device … Read more

David Douglass - Director - Delphi Ventures

Since 1979, David has been actively involved in managing and investing in over 50 high growth venture capital backed companies, primarily in the medical device industry. He joined Delphi Ventures in 1990. Prior to joining Delphi, David was a General Partner at Matrix Partners focusing on medical device investments.

From 1984 to 1986, David served as Chief Operating Officer at Paladin Software Corporation, responsible for operations, R&D, finance and administration.

From 1979 to 1983, David was Vice President of Finance and Administration at Collagen Corporation. He was responsible for several private equity financings, as well as Collagen’s initial public offering. Before joining Collagen, David was a consultant with McKinsey & Company and a Teaching Fellow at Athens College in Greece.

David is a trustee of the Stanford University DAPER Fund and is a member of the Stanford University School of Education Advisory Board. He has served as a director of the Stanford University Athletic Board. Additionally, David is an Adjunct Professor at The University of Hawaii teaching New Venture Management and is a member of the Medical Industry Group of the National Venture Capital Association. Previously, he served as a director of the Western Association of Venture Capital. Recently, David was named to the Forbes Midas List recognizing the top 100 venture capital investors.

David earned his BA cum laude in political science from Amherst College and received an MBA and MA in Education from Stanford University.

Charles Carignan MD

CEO and Director- Rex Bionics

Chuck brings over 20 years of experience in medical device development. He has vast experience as a clinician, med-tech executive and CEO. He has had … Read more

Charles Carignan MD - CEO and Director- Rex Bionics

Chuck brings over 20 years of experience in medical device development. He has vast experience as a clinician, med-tech executive and CEO. He has had the opportunity to introduce a number of breakthrough technologies that have changed healthcare, navigating the clinical, regulatory and reimbursement challenges along the way. Before joining Rex Bionics he was the CEO of BionX (sold to Ottobock), and was founder and CEO of Ninepoint Medical, a developer of medical devices that enable high resolution in-vivo imaging. At NinePoint, he was able to bring together an outstanding team who developed and launched the first product within 3 years of licensing the fundamental technology from Massachusetts General Hospital. Prior to that, Chuck was Executive Vice President and Chief Medical Officer of Novasys Medical, Inc., where he was responsible for the successful launch of a device to treat stress urinary incontinence. Prior to Novasys, he was Chief Medical Officer at Boston Scientific, and Vice President of clinical research and medical affairs at Conceptus. Chuck has served healthcare worldwide participating on committees of the U.S. Food and Drug Administration, Centers for Medicare & Medicaid Services, the World Health Organization, the United Nations, and the U.S. Agency for International Development. Chuck trained in general surgery at Columbia-Presbyterian Medical Center. He earned his undergraduate degree from Yale University and his MD degree from the College of Physicians and Surgeons of Columbia University. Chuck joined Rex Bionics in June 2017.

Michael Hoey

Director – NxThera

Michael co-founded NxThera in 2008 to develop and commercialize the urology applications of the vapor platform technology that he invented. Michael has been a Director and Chief … Read more

Michael Hoey - Director – NxThera

Michael co-founded NxThera in 2008 to develop and commercialize the urology applications of the vapor platform technology that he invented. Michael has been a Director and Chief Technology Officer since NxThera’s inception. Prior to becoming an entrepreneur, Michael taught in several departments and performed research at the University of Minnesota, including the Department of Physiology, the Department of Urologic Surgery in the School of Medicine, the Institute of Technology, and the Carlson School of Management. Michael also taught in the department of Biological Sciences at Hamline University in St. Paul, Minnesota. Michael is an expert in the interaction of thermotherapy and tissue and a prolific inventor, with 72 patents granted and 94 patents pending, the majority of which are in the medical device field.

Michael’s inventions include platform technologies, which are the foundation for products being sold, or in development for a variety of cardiac surgery, oncology, orthopaedics, pulmonology, general surgery, urology, gynecology, and vascular surgery applications. Michael has been a consultant to, as well as a founder/principal of, several medical products companies, which combined have raised over $250 million of capital.

Bruce Steel

Director – BioMed Ventures

Bruce D. Steel has served as BioMed Ventures Managing Director since September 2010. From 2005 until its acquisition in 2008, Bruce was Chief Executive Officer and Co-Founder … Read more

Bruce Steel - Director – BioMed Ventures

Bruce D. Steel has served as BioMed Ventures Managing Director since September 2010. From 2005 until its acquisition in 2008, Bruce was Chief Executive Officer and Co-Founder of Rincon Pharmaceuticals, a genetic engineering biotechnology and biofuels company. Bruce was also previously Chief Business Officer at Anaphore and Head of Corporate Development at Ambit Biosciences. He received his Bachelor of Arts Degree from Dartmouth College and his Masters of Business Administration Degree from the Marshall School of Business at the University of Southern California. Mr. Steel holds the designation of Chartered Financial Analyst.


Important Safety Information:

The Mara Water Vapor Ablation System is indicated to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia due to benign causes for whom childbearing is complete. Pregnancy following the Mara procedure can be dangerous. The Mara procedure is not for those who have or suspect uterine cancer; have an active genital, urinary or pelvic infection; or an IUD. As with all surgical procedures, there are risks and considerations associated with the use of the Mara Water Vapor Ablation System. Please refer to the device labeling for a detailed discussion of the device’s intended use, relevant warnings, precautions, side effects, and contraindications.